Anti-inflammation of Erianin in dextran sulphate sodium-induced ulcerative colitis mice model via collaborative regulation of TLR4 and STAT3

Dou, Bo; Hu, Wenjing; Song, Minkai; Lee, Robert J.; Zhang, Xiaoyu; Wang, Di

doi:10.1016/j.cbi.2020.109089

Cited by 27 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herbal medicine is one of the most traditional culture in China, and derivation of the biologically active molecules from Chinese medicine plays important roles in drug screening. Erianin, derived from Dendrobium, has shown to have effects on different cellular progress, for example, It have the activity in anti-bacterial infections [24] , and could exert its anti-inflammatory effect in mouse model of ulcerative colitis [25] and diabetic nephropathy model [26] , moreover, it reduced high glucose induced renal tubular epithelial cell damage [27] , furthermore some studies have shown block blood vessel formation [21,28,29] . While the among them the anticancer activity of erianin was most reported [30] , which could affect the proliferation, apoptosis, autophagy, metastasis and angiogenesis of cancer cells, the main pathways involved are the JNK, ERK, and p53 pathways.…”

Section: Discussionmentioning

confidence: 99%

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway

Fang

Shao

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is a refractory subtype of breast cancer, 25-30% of which have dysregulation in the PI3K/AKT pathway. This study investigated the anti-cancer effect of erianin on triple-negative breast cancer cell line and its underlying mechanism. Methods: After treatment with erianin, MTT assay was employed to determine the MDA-MB-231 and EFM-192A cell proliferation, the nucleus morphological changes were observed by DAPI staining. The cell cycle and apoptotic proportion were detected by flow cytometry. Western blot was performed to determine the cell cycle and apoptosis-related protein expression and PI3K pathways. Finally, the anti-proliferation activity of erianin was further confirmed by adding or not adding PI3K agonists SC79. Results: Erianin inhibited the proliferation of MDA-MB-231 and EFM-192A cells in a dose-dependent manner, the IC50 were 70.96 nM and 78.58 nM, respectively. Erianin could cause cell cycle arrest at the G2/M phase, and the expressions of p21, p27 were upregulated, while the expressions of CDK1 and Cyclin B1 were downregulated. Erianin also induced apoptosis via the mitochondrial pathway, with the upregulation of the expression of Cyto C, PARP, Bax, activity form of Caspase-3, and Caspase-9. Furthermore, p-PI3K and p-Akt expression were downregulated by erianin. After co-incubation with SC79, the cell inhibition rate of erianin was decreased, which further confirmed that the attenuated PI3K/Akt pathway was relevant to the pro-apoptotic effect of erianin. Conclusions: Erianin can inhibit the proliferation of TNBC cells and induce cell cycle arrest and apoptosis, which may ascribe to the abolish the activation of the PI3K/Akt pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway

Fang

Shao

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Growing evidence suggests that various immune cells contribute to tumor progression when present in the tumor microenvironment (TME). A study has found that erianin can reduce immune inflammatory responses in dextran sulfate sodium–induced ulcerative colitis, possibly via activating TLR4 (Toll-like receptor 4) and STAT3 (signal transducer and activator of transcription 3) signaling pathways ( Dou et al, 2020 ). Recently, researchers found that erianin can modulate immune response to exert its anti-carcinogenesis property in liver cancer cells ( Zhang et al, 2019a ).…”

Section: Resultsmentioning

confidence: 99%

“…Among these bibenzyl compounds, erianin was determined as the typical chemical marker from Dendrobium chrysotoxum ( Xie et al, 2021 ). Modern pharmacological studies have shown that erianin can exert therapeutic activities under various disease conditions such as tumors ( Liu et al, 2019a ; Chen et al, 2020a ; Dong et al, 2020 ), inflammation ( Zhang et al, 2019a ; Zhang et al, 2019b ; Dou et al, 2020 ; Yang et al, 2021 ), and oxidative injury ( Chen et al, 2019 ). In this study, we focus on the anti-tumor activities of erianin and its underlying mechanism of action.…”

Section: Introductionmentioning

confidence: 99%

Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology

Yan

Zhang

Liu

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Erianin is a major bisbenzyl compound extracted from Dendrobium chrysotoxum Lindl., an important traditional Chinese herb. In recent years, a growing body of evidence has proved the potential therapeutic effects of erianin on various cancers, including hepatoma, melanoma, non-small-cell lung carcinoma, myelogenous leukemia, breast cancer, and osteosarcoma. Especially, the pharmacological activities of erianin, such as antioxidant and anticancer activity, have been frequently demonstrated by plenty of studies. In this study, we firstly conducted a systematic review on reported anticancer activity of erianin. All updated valuable information regarding the underlying action mechanisms of erianin in specific cancer was recorded and summarized in this paper. Most importantly, based on the molecular structure of erianin, its potential molecular targets were analyzed and predicted by means of the SwissTargetPrediction online server (http://www.swisstargetprediction.ch). In the meantime, the potential therapeutic targets of 10 types of cancers in which erianin has been proved to have anticancer effects were also predicted via the Online Mendelian Inheritance in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/omim). The overlapping targets may serve as valuable target candidates through which erianin exerts its anticancer activity. The clinical value of those targets was subsequently evaluated by analyzing their prognostic role in specific cancer using Kaplan-Meier plotter (http://Kmplot.com/analysis/) and Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/). To better assess and verify the binding ability of erianin with its potential targets, molecular flexible docking was performed using Discovery Studio (DS). The valuable targets obtained from the above analysis and verification were further mapped to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) to explore the possible signaling pathways disturbed/regulated by erianin. Furthermore, the in silico prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of erianin was also performed and provided in this paper. Overall, in this study, we aimed at 1) collecting all experiment-based important information regarding the anticancer effect and pharmacological mechanism of erianin, 2) providing the predicted therapeutic targets and signaling pathways that erianin might act on in cancers, and 3) especially providing in silico ADMET properties of erianin.

show abstract

“…no. 23227; Thermo Fisher Scientific, Inc.) as previously described (24). A total of 100 µg total protein of each group was diluted to 1 mg/ml and mixed with 4 volumes of cold acetone.…”

Section: Animal Experimentsmentioning

confidence: 99%

Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects

Zhang

Zhao

et al. 2022

Mol Med Rep

View full text Add to dashboard Cite

evodiamine (evo) is an alkaloid that can be extracted from the berry fruit Evodia rutaecarpa and has been reported to exert various pharmacological effects, such as antidiarrheal, antiemetic and antiulcer effects. In vivo, the potential effects of evo were investigated in a mouse model of dextran sodium sulfate (dSS)-induced ulcerative colitis (uc) and in adenomatous polyposis coli (apc) Minc /Gpt c57Bl/6 mice with colorectal cancer (crc), where the latter harbours a point-mutation in the Apc gene. evo suppressed the degree of weight loss and colon shortening induced by dSS, decreased the disease activity index value and ameliorated the pathological alterations in the colon of mice with uc as examined via H&e staining of colon tissues. in addition, evo decreased the number and size of colonic tumors in apc Minc /Gpt mice. Proteomics (colon tissues), eliSa (colon tissues and serum) and western blotting (colon tissues) results revealed that evo inhibited nF-κB to mediate the levels of various cytokines, including, in the dSS-induced uc model, il-1β, il-2, il-6, il-8, TnF-α, iFn-γ (eliSa of colon tissues and serum), nF-κB, iKKα+β, iκBα, S100a9, Tlr4 and Myd88 (western blotting of colon tissues), and, in the colorectal cancer model, il-1β, il-2, il-6, il-15, il-17, il-22, TnF-α (eliSa of colon tissues and serum), nF-κB, iKKα+β, iκBα and S100a9 (western blotting of colon tissues), to achieve its anti-inflammatory and antitumor effects. In vitro, evo also reduced the viability of the colon cancer cell line SW480, inhibited mitochondrial membrane potential (MMP detection), caused G 2 /M-phase arrest (cell cycle detection) and suppressed the translocation of phosphorylated-nF-κB from the cytoplasm into the nucleus (immunofluorescence of p-NF-κB). Theoretical evidence (Md simulations) suggest that evo may bind to the ordered domain (α-helix) of nF-κB to influence this protein. The protein secondary structure changes were analyzed by the cpptraj module in amber. in addition, these data provide experimental evidence that evo may be an effective agent for treating uc and crc.

show abstract

Anti-inflammation of Erianin in dextran sulphate sodium-induced ulcerative colitis mice model via collaborative regulation of TLR4 and STAT3

Cited by 27 publications

References 56 publications

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway

Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology

Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects

Contact Info

Product

Resources

About